Literature DB >> 27013239

Oxygen therapy for cluster headache. A mask comparison trial. A single-blinded, placebo-controlled, crossover study.

Anja S Petersen1, Mads Cj Barloese1, Nunu Lt Lund1, Rigmor H Jensen1.   

Abstract

Purpose The purpose of this article is to investigate possible differences in effect between three types of masks in the acute treatment of cluster headache (CH). Patients and methods Fifty-seven CH patients according to ICHD-II-criteria participated in a single-blinded, semi-randomized, placebo-controlled, crossover inpatient study, and 102 CH attacks were treated with 100% oxygen delivered by demand valve oxygen (DVO), O2ptimask or simple mask (15 liters/min) or placebo delivered by DVO for 15 minutes. Primary endpoint: Two-point decrease of pain on a five-point rating scale within 15 minutes. Results Only 10 CH patients had multiple attacks and reached the point of placebo. There were no significant differences between masks in the primary endpoints ( p = 0.412). After 15 minutes 48% had a two-point decrease using the DVO compared to 45% with placebo ( p = 0.867). After 30 minutes 68% were pain free or had pain relief using DVO and 45% by placebo ( p = 0.061). The DVO was preferred by 62% compared to 5% and 33% for simple mask ( p < 0.0001) and O2ptimask ( p = 0.061). In the first attack the DVO was significantly better at achieving pain relief at 15 minutes ( p = 0.018). Treatment with DVO or O2ptimask reduced the need for rescue medication compared to the simple mask (23%, 19%, 50%, respectively). No treatment-related adverse events were observed. Conclusion The primary endpoint with pain relief at 15 minutes was non-significant; however, a post hoc analysis of the first attack significantly favored DVO. Further, therapy by O2ptimask and DVO resulted in a decreased need for rescue medication. We recommend that CH patients be offered DVO or O2ptimask before oxygen therapy is abandoned.

Entities:  

Keywords:  Cluster headache; mask types; oxygen treatment; randomized controlled trial

Mesh:

Substances:

Year:  2016        PMID: 27013239     DOI: 10.1177/0333102416637817

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  7 in total

Review 1.  Oxygen Therapy in Cluster Headache, Migraine, and Other Headache Disorders.

Authors:  Heejung Mo; Soo Jie Chung; Todd D Rozen; Soo-Jin Cho
Journal:  J Clin Neurol       Date:  2022-05       Impact factor: 2.566

Review 2.  Cluster headache pathophysiology - insights from current and emerging treatments.

Authors:  Diana Y Wei; Peter J Goadsby
Journal:  Nat Rev Neurol       Date:  2021-03-29       Impact factor: 42.937

3.  Effectiveness of Oxygen and Other Acute Treatments for Cluster Headache: Results From the Cluster Headache Questionnaire, an International Survey.

Authors:  Stuart M Pearson; Mark J Burish; Robert E Shapiro; Yuanqing Yan; Larry I Schor
Journal:  Headache       Date:  2019-01-11       Impact factor: 5.887

Review 4.  Pharmacotherapy for Cluster Headache.

Authors:  Roemer B Brandt; Patty G G Doesborg; Joost Haan; Michel D Ferrari; Rolf Fronczek
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

5.  Managing cluster headache.

Authors:  Diana Y Wei; Modar Khalil; Peter J Goadsby
Journal:  Pract Neurol       Date:  2019-07-05

6.  Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd edition, 2020.

Authors:  Henrik W Schytz; Faisal M Amin; Rigmor H Jensen; Louise Carlsen; Stine Maarbjerg; Nunu Lund; Karen Aegidius; Lise L Thomsen; Flemming W Bach; Dagmar Beier; Hanne Johansen; Jakob M Hansen; Helge Kasch; Signe B Munksgaard; Lars Poulsen; Per Schmidt Sørensen; Peter T Schmidt-Hansen; Vlasta V Cvetkovic; Messoud Ashina; Lars Bendtsen
Journal:  J Headache Pain       Date:  2021-04-08       Impact factor: 7.277

Review 7.  Drug Treatment of Cluster Headache.

Authors:  Hans Christoph Diener; Arne May
Journal:  Drugs       Date:  2021-12-17       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.